Piper Sandler on Supernus Pharmaceuticals (SUPN): 'Favorable Feedback On Onapgo From Expert Call'
Tweet Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $65.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
